Last reviewed · How we verify
BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE
This is a quadruple therapy combining bismuth subsalicylate, tetracycline, metronidazole, and omeprazole to eradicate Helicobacter pylori through multiple antimicrobial and acid-suppression mechanisms.
This is a quadruple therapy combining bismuth subsalicylate, tetracycline, metronidazole, and omeprazole to eradicate Helicobacter pylori through multiple antimicrobial and acid-suppression mechanisms. Used for Helicobacter pylori infection eradication in peptic ulcer disease, H. pylori-associated gastritis.
At a glance
| Generic name | BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE |
|---|---|
| Also known as | PYLERA, OTC OMEPRAZOLE |
| Sponsor | The University of Texas Health Science Center, Houston |
| Drug class | H. pylori eradication therapy (quadruple therapy) |
| Target | Helicobacter pylori (bacterial pathogen); omeprazole targets H+/K+-ATPase |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Bismuth acts as a bactericidal agent and mucosal protectant, tetracycline and metronidazole are broad-spectrum antibiotics effective against H. pylori, and omeprazole is a proton pump inhibitor that reduces gastric acid to create an environment favorable for antibiotic activity. This combination approach targets the bacterium through multiple pathways while protecting the gastric mucosa, significantly improving eradication rates compared to dual or triple therapies.
Approved indications
- Helicobacter pylori infection eradication in peptic ulcer disease
- H. pylori-associated gastritis
Common side effects
- Nausea
- Diarrhea
- Abdominal discomfort
- Metallic taste (from metronidazole)
- Photosensitivity (from tetracycline)
- Black stool (from bismuth)
Key clinical trials
- Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding" (PHASE3)
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial (NA)
- Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis (PHASE4)
- Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans (PHASE3)
- Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma (PHASE2)
- Doxycycline for Helicobacter Pylori Rescue Treatment (PHASE4)
- Rescue Therapy for Helicobacter Pylori Eradication Treatment (PHASE4)
- Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: